How to Source Tenofovir DF + Emtricitabine + Rilpivirine for Pharmaceutical Formulation
Tenofovir DF + Emtricitabine + Rilpivirine (Tablet, TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg) is classified under Anti Viral. It is therapeutically aligned with reference brands such as Complera(US); Eviplera(EU). This guide highlights key sourcing factors buyers should consider when procuring high-quality Tenofovir DF + Emtricitabine + Rilpivirine for formulation, R&D, or bulk manufacturing.
Product Overview:
Tenofovir DF + Emtricitabine + Rilpivirine, sold as Complera (US) and Eviplera (EU), is a once-daily HIV-1 treatment combining three antiretrovirals in one tablet. It’s FDA and EMA approved and must be taken with food.
Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Rilpivirine is a once-daily, fixed-dose combin...
Tenofovir DF + Emtricitabine + Rilpivirine API – ideal for compliant pharmaceutical formulation.
Quick Insight: Over 60% of formulation delays are linked to poor API sourcing. A well-planned sourcing strategy can reduce risk and accelerate market entry.
1. Regulatory Compliance & Documentation
Ensure suppliers provide:
- ✔ Valid DMF (Drug Master File)
- ✔ COA (Certificate of Analysis) for each batch
- ✔ GMP, ISO, or ICH Q7 compliance certificates
2. Purity, Grade & Specification Matching
Tenofovir DF + Emtricitabine + Rilpivirine must meet exact grade and purity for your dosage form:
- ✔ USP / EP / JP grade verification
- ✔ Particle size distribution check
- ✔ Residual solvent and heavy metal limits
3. Supplier Reliability & Audit History
- ✔ Positive past audit reports
- ✔ Pharma client references
- ✔ Years of proven API manufacturing experience
4. Commercial Terms: Pricing, MOQ & Flexibility
- ✔ Transparent pricing
- ✔ Pilot batch MOQ flexibility
- ✔ Volume-based discounts
5. Lead Time, Inventory & Logistics
Typical lead time for Tenofovir DF + Emtricitabine + Rilpivirine is 4–6 weeks.
- ✔ Emergency dispatch options
- ✔ Regional warehousing
- ✔ Special storage if needed
6. Formulation Support
- ✔ Technical datasheets
- ✔ Sample availability
- ✔ Stability study support
Pro Tip: Engage supplier formulation experts early — it can improve bioavailability and cut development time.
Conclusion
Sourcing Tenofovir DF + Emtricitabine + Rilpivirine is more than procurement—it’s a strategic partnership. With its tablet form and TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.
Next Step: Get expert assistance in sourcing Tenofovir DF + Emtricitabine + Rilpivirine.
Request a Quote
Frequently Asked Questions For Sourcing of Tenofovir DF + Emtricitabine + Rilpivirine
What is the typical lead time for Tenofovir DF + Emtricitabine + Rilpivirine?
Lead times range from 4–6 weeks depending on supplier and region.
Is Tenofovir DF + Emtricitabine + Rilpivirine available in multiple grades?
Yes — common grades include USP, EP, and JP. Verify grade suitability for your dosage form before purchase.
Does Tenofovir DF + Emtricitabine + Rilpivirine require special storage?
It should be stored in a cool, dry place away from direct sunlight.
Is a Drug Master File (DMF) available for Tenofovir DF + Emtricitabine + Rilpivirine?
Yes, a DMF is available for regulated markets upon request. It includes detailed quality, manufacturing, and stability data.
Can I request samples or a pilot batch of Tenofovir DF + Emtricitabine + Rilpivirine?
Yes — pilot batches or samples can be arranged for R&D, stability studies, or formulation trials. MOQ may vary based on region and regulatory scope.
What compliance certificates are available for Tenofovir DF + Emtricitabine + Rilpivirine?
Available documentation may include GMP, ISO 9001, ISO 14001, and ICH Q7 certificates, along with CoA, TDS, and stability data.
Is Tenofovir DF + Emtricitabine + Rilpivirine suitable for regulated markets like US/EU?
Yes — compliant with EU/US/WHO GMP standards and available with regulatory support documentation for filings.
Can Tenofovir DF + Emtricitabine + Rilpivirine be used in fixed-dose combinations?
Yes — many formulations support inclusion in FDCs. Compatibility studies and formulation consultation are available on request.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our
Privacy Policy.